The therapeutic landscape for HER2-neg metastatic breast cancer (HER2-neg MBC) is rapidly changing with the addition of antibody drug-conjugate (ADC) therapies. As a result, clinicians are not confident or knowledgeable in applying emerging clinical data to…
Delayed diagnosis of cervical cancer often leads to poor prognosis and lower survival rates, especially in advanced stages. Recent therapeutic advancements, including immune-checkpoint inhibitors and ADCs, offer new hope for managing advanced cervical cancer. However, there…
Ovarian cancer typically responds well to initial platinum-based chemotherapy treatment. However, most tumors subsequently relapse and eventually become resistant, for which the prognosis is poor and no therapeutic options which have shown substantial OS benefit. Further,…
As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present…
Despite advancements in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), resistance and recurrence occur frequently and mutations might develop during treatment. Given the diverse range of treatment side effects,…
In the United States, diffuse large B-cell lymphoma (DLBCL) has an incidence rate of 5.5-7.2 per 100,000 individuals, and a death rate of 1.7 per 100,000. Despite its prevalence, integrating the necessary diagnostic and prognostic markers…
Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and…
The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical cancer is associated with inefficiencies…
Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis)…
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on emerging trial…